Angiogenesis Analytics provides PCaVision, an AI-powered software that analyzes multi-modal 3D ultrasound data to identify suspicious regions in prostate cancer diagnosis. This solution streamlines the diagnostic workflow, enabling urologists to perform targeted biopsies with greater accuracy and efficiency.
Funding
Funding not disclosed
Founders
Product
Problem
Current prostate cancer diagnostic pathways often involve lengthy waiting times and significant costs, particularly those relying on MRI-guided biopsies. Standard systematic biopsies, while less costly, have limited sensitivity and can be invasive, leading to potential underdiagnosis or unnecessary procedures.
Solution
Angiogenesis Analytics offers PCaVision, an AI-powered software solution that enhances ultrasound-based prostate cancer diagnosis. The system analyzes multi-modal 3D ultrasound data, including B-mode, elastography, and contrast-enhanced ultrasound, to generate precise heatmaps identifying suspicious regions. This approach streamlines the diagnostic workflow, enabling urologists to perform targeted biopsies with greater accuracy and efficiency. By integrating advanced imaging analysis directly into the clinical setting, PCaVision aims to reduce diagnostic turnaround times and improve patient outcomes.
Target Audience
The primary target audience includes urologists and healthcare providers involved in prostate cancer diagnostics who seek to improve the accuracy and efficiency of their biopsy procedures.
Features
- AI-driven analysis of 3D transrectal ultrasound (TRUS) data, including B-mode, shear wave elastography (SWE), and contrast-enhanced ultrasound (CEUS).
- Generation of 3D heatmaps that visually highlight clinically significant prostate cancer (csPCa) regions of interest.
- Software interface compatible with DICOM standards for seamless integration into existing PACS and reporting workflows.
- Capability to generate cognitive targeted biopsy (TBx) reports or fusion export files for precise lesion localization.
- Reduced diagnostic pathway time, with results available within minutes of image acquisition.
- Designed for execution by experienced urologists with minimal specialized training required after initial procedures.
- Offers a cost-effective alternative to MRI-guided pathways, potentially increasing access to advanced diagnostics.
- Supports a significant reduction in the number of biopsies performed compared to systematic biopsy approaches.